These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1631568)

  • 1. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants.
    Hauptmann J; Markwardt F
    Semin Thromb Hemost; 1992; 18(2):200-17. PubMed ID: 1631568
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new generation of anticoagulants: design, synthesis and pharmacologic profile of thrombin inhibtors].
    Schmid G; Ackermann J; Banner D; Gast A; Gubernator K; Hadváry P; Hilpert K; Labler L; Tschopp T
    J Pharm Belg; 1995; 50(2-3):188-93. PubMed ID: 7674118
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of lactobionic acid on the kinetics of thrombin in human plasma.
    Béguin SS; Dol F; Hemker HC
    Semin Thromb Hemost; 1991; 17 Suppl 1():126-8. PubMed ID: 2068565
    [No Abstract]   [Full Text] [Related]  

  • 4. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct thrombin inhibitors.
    Maffrand JP
    Nouv Rev Fr Hematol (1978); 1992; 34(6):405-19. PubMed ID: 1300540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Lewis BE; Bick RL; Walenga JM
    Semin Hematol; 1999 Jan; 36(1 Suppl 1):42-56. PubMed ID: 9930564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin inhibitors (part 1 of 2).
    Arora UK; Dhir M
    J Invasive Cardiol; 2005 Jan; 17(1):34-8. PubMed ID: 15640538
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.
    Turpie AG
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 10. New antithrombotic drugs.
    Gross PL; Weitz JI
    Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
    Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant and antithrombotic action of novel specific inhibitors of thrombin.
    Hauptmann J; Kaiser B; Markwardt F; Nowak G
    Thromb Haemost; 1980 Jun; 43(2):118-23. PubMed ID: 7455968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
    Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombin].
    Camici M; Sagripanti A; Di Mitri R
    Minerva Med; 2000; 91(5-6):105-12. PubMed ID: 11084844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
    Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
    J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and biological activity of dipeptides containing S-hexylcysteine.
    Bruzgo I; Midura-Nowaczek K
    Acta Pol Pharm; 2007; 64(5):479-82. PubMed ID: 18540170
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.